Newsfile Corp
11 Jul 2026, 00:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Grail announced on February 19, 2026, that the primary endpoint of statistically significant Stage III-IV cancer reduction was not observed in the NHS-Galleri Trial. — Failure to meet a primary clinical endpoint for a core product is a fundamental blow to the company's value proposition and growth prospects.
-0.80A class action lawsuit has been filed alleging that Grail executives made false or misleading statements regarding the probability of the NHS-Galleri trial's success. — Securities litigation introduces significant legal liability, potential settlement costs, and reputational damage to management.
-0.40Grail's stock price fell by more than 50% following the announcement of the failed NHS-Galleri trial endpoint. — This confirms a massive loss of market capitalization and a high level of investor sensitivity to the trial results.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is facing a class action lawsuit alleging securities fraud and the failure of a primary trial endpoint, resulting in a 50% stock price drop.
The company is mentioned in an investor deadline notice regarding a class action lawsuit for investors with substantial losses.
The company is mentioned in an investor alert regarding a class action lawsuit for investors with substantial losses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
